Zobrazeno 1 - 10
of 699
pro vyhledávání: '"Hiroaki Mitsuya"'
Autor:
Yoshiaki Yasutake, Shin-ichiro Hattori, Hiroki Kumamoto, Noriko Tamura, Kenji Maeda, Hiroaki Mitsuya
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract While certain human hepatitis B virus-targeting nucleoside analogs (NAs) serve as crucial anti-HBV drugs, HBV yet remains to be a major global health threat. E-CFCP is a 4′-modified and fluoromethylenated NA that exhibits potent antiviral
Externí odkaz:
https://doaj.org/article/059c8c1e028d492c949cb0d19dc9fde6
Autor:
Masayuki Amano, Sachiko Otsu, Yukari Uemura, Yasuko Ichikawa, Shota Matsumoto, Nobuyo Higashi-Kuwata, Shuzo Matsushita, Shinya Shimada, Hiroaki Mitsuya
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract SARS-CoV-2-BA.4/5-adapted-bivalent-BNT162b2-vaccine (bvBNT), developed in response to the recent emergence of immune-evasive Omicron-variants, has been given to individuals who completed at least 2-doses of the monovalent-BNT162b2-vaccine (m
Externí odkaz:
https://doaj.org/article/cd48da40d4f84c6b89e3b7d9ef7900f9
Autor:
Shohei Yamamoto, Kouki Matsuda, Kenji Maeda, Yusuke Oshiro, Natsumi Inamura, Tetsuya Mizoue, Maki Konishi, Junko S. Takeuchi, Kumi Horii, Mitsuru Ozeki, Haruhito Sugiyama, Hiroaki Mitsuya, Wataru Sugiura, Norio Ohmagari
Publikováno v:
BMC Infectious Diseases, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Longitudinal data are lacking to compare booster effects of Delta breakthrough infection versus third vaccine dose on neutralizing antibodies (NAb) against Omicron. Methods Participants were the staff of a national research and me
Externí odkaz:
https://doaj.org/article/d0605f87e451440196f540c6a5afcbf1
Autor:
Noriko Iwamoto, Yuki Takamatsu, Yusuke Asai, Kiyoto Tsuchiya, Kouki Matsuda, Yusuke Oshiro, Natsumi Inamura, Mari Terada, Takashi Nemoto, Moto Kimura, Sho Saito, Shinichiro Morioka, Maeda Kenji, Hiroaki Mitsuya, Norio Ohmagari
Publikováno v:
Heliyon, Vol 10, Iss 2, Pp e24513- (2024)
Background: Antibody testing can easily evaluate the clinical status of patients, aid in the diagnosis of multisystem inflammatory syndrome, and monitor the immunity level in the population. However, the applicability of serological tests in detectin
Externí odkaz:
https://doaj.org/article/9da9f5b755b44a158e730dbc689e86db
Autor:
Shohei Yamamoto, Kouki Matsuda, Kenji Maeda, Kumi Horii, Kaori Okudera, Yusuke Oshiro, Natsumi Inamura, Junko S. Takeuchi, Maki Konishi, Mitsuru Ozeki, Tetsuya Mizoue, Haruhito Sugiyama, Nobuyoshi Aoyanagi, Hiroaki Mitsuya, Wataru Sugiura, Norio Ohmagari
Publikováno v:
International Journal of Infectious Diseases, Vol 128, Iss , Pp 347-354 (2023)
Objectives: To investigate the role of immunogenicity after the third vaccine dose against Omicron infection and COVID-19-compatible symptoms of infection. Methods: First, we examined vaccine effectiveness (VE) of the third dose against the second do
Externí odkaz:
https://doaj.org/article/fec3573d884a494d9dd25717a6e815d2
Autor:
Nobuyo Higashi-Kuwata, Kohei Tsuji, Hironori Hayashi, Haydar Bulut, Maki Kiso, Masaki Imai, Hiromi Ogata-Aoki, Takahiro Ishii, Takuya Kobayakawa, Kenta Nakano, Nobutoki Takamune, Naoki Kishimoto, Shin-ichiro Hattori, Debananda Das, Yukari Uemura, Yosuke Shimizu, Manabu Aoki, Kazuya Hasegawa, Satoshi Suzuki, Akie Nishiyama, Junji Saruwatari, Yukiko Shimizu, Yoshikazu Sukenaga, Yuki Takamatsu, Kiyoto Tsuchiya, Kenji Maeda, Kazuhisa Yoshimura, Shun Iida, Seiya Ozono, Tadaki Suzuki, Tadashi Okamura, Shogo Misumi, Yoshihiro Kawaoka, Hirokazu Tamamura, Hiroaki Mitsuya
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-13 (2023)
Effective antivirals are critical for combatting SARS-CoV-2 infections. Here, the authors develop two orally available small molecules, which specifically inhibit the activity of the SARS-CoV-2 main protease and potently block the infectivity and rep
Externí odkaz:
https://doaj.org/article/0a9319e808d143a0af10cb89193b1a4f
Autor:
Kiyoto Tsuchiya, Kenji Maeda, Kouki Matsuda, Yuki Takamatsu, Noriko Kinoshita, Satoshi Kutsuna, Tsunefusa Hayashida, Hiroyuki Gatanaga, Norio Ohmagari, Shinichi Oka, Hiroaki Mitsuya
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-7 (2023)
Abstract Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluated the anti-SARS-CoV-2 antibody levels, anti-spike (S)-immunoglobulin G (IgG) and anti-nucleocapsid (N)-IgG, and the neu
Externí odkaz:
https://doaj.org/article/1347932994f84bbb9e5e8a02d744f4e5
Autor:
Junko S. Takeuchi, Ami Fukunaga, Shohei Yamamoto, Akihito Tanaka, Kouki Matsuda, Moto Kimura, Azusa Kamikawa, Yumiko Kito, Kenji Maeda, Gohzoh Ueda, Tetsuya Mizoue, Mugen Ujiie, Hiroaki Mitsuya, Norio Ohmagari, Wataru Sugiura
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract The humoral and cellular immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) upon the coronavirus disease 2019 (COVID-19) vaccination remain to be clarified. Hence, we aimed to investigate the long-term chro
Externí odkaz:
https://doaj.org/article/7b66c86b6e6542ae9c3f1916ebc675d9
Autor:
Masayuki Amano, Sachiko Otsu, Kenji Maeda, Yukari Uemura, Yosuke Shimizu, Kazumi Omata, Masao Matsuoka, Shinya Shimada, Hiroaki Mitsuya
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-13 (2022)
Abstract In the present prospective study, 225 individuals in Kumamoto General Hospital, Japan, who received two-doses of BNT162b2 vaccine were enrolled/followed up over 150 days and neutralizing activity (NT50) of their sera and antiviral activity (
Externí odkaz:
https://doaj.org/article/00d09dd1afa44e46b346c688df487bcc
Autor:
Misaki Ishibane, Hirofumi Hashimoto, Meika Kaneko, Shota Saito, Sangjon Pae, Shinpei Saito, Yoshie Reien, Yuri Hirayama, Nobuyo Higashi-Kuwata, Hiroaki Mitsuya, Naohiko Anzai
Publikováno v:
Journal of Pharmacological Sciences, Vol 150, Iss 4, Pp 201-203 (2022)
Currently, the emergence of drug resistance is an important issue in the treatment of hepatitis B virus (HBV). Recently, our collaborating group developed a novel long-acting anti-HBV drug, E-CFCP. However, until this study, the effects of E-CFCP in
Externí odkaz:
https://doaj.org/article/4bc5d2803a814859b0f5e5642f691b2f